Marvin E. Jaffe
Director/Miembro de la Junta en Matrix Pharmaceuticals, Inc. .
Perfil
Marvin E.
Jaffe is currently a Director at Matrix Pharmaceuticals, Inc. and a Partner at Naimark & Associates PC.
He previously served as a Director at Immunomedics, Inc., NeoGenomics, Inc., Allos Therapeutics, Inc., Celltech Group Plc, Genta, Inc., Genetic Therapy, Inc., Vernalis Group Plc, Merck & Co., Inc., Organon Pharma (UK) Ltd., and as the Founding President of R.W.
Johnson Pharmaceutical Research Institute.
Dr. Jaffe holds a doctorate degree from Thomas Jefferson University.
Cargos activos de Marvin E. Jaffe
| Empresas | Cargo | Inicio |
|---|---|---|
| Matrix Pharmaceuticals, Inc. | Director/Miembro de la Junta | 05/04/2010 |
| Naimark & Associates PC | Corporate Officer/Principal | 05/04/2010 |
Antiguos cargos conocidos de Marvin E. Jaffe.
| Empresas | Cargo | Fin |
|---|---|---|
| NEOGENOMICS, INC. | Director/Miembro de la Junta | 03/02/2011 |
| IMMUNOMEDICS, INC. | Director/Miembro de la Junta | 27/08/2009 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Director/Miembro de la Junta | 10/05/2006 |
| R.W. Johnson Pharmaceutical Research Institute | Presidente | 01/01/1994 |
Genta, Inc.
 Genta, Inc. Pharmaceuticals: MajorHealth Technology Genta, Inc. is in the process of bankruptcy. The company formerly engages in pharmaceutical research and development. Genta was founded on February 4, 1988 and is headquartered in Berkeley Heights, NJ. | Director/Miembro de la Junta | - |
Formación de Marvin E. Jaffe.
| Thomas Jefferson University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| NEOGENOMICS, INC. | Health Services |
| Empresas privadas | 10 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Genta, Inc.
Genta, Inc. Pharmaceuticals: MajorHealth Technology Genta, Inc. is in the process of bankruptcy. The company formerly engages in pharmaceutical research and development. Genta was founded on February 4, 1988 and is headquartered in Berkeley Heights, NJ. | Health Technology |
Genetic Therapy, Inc.
 Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Commercial Services |
Organon Pharma (UK) Ltd.
 Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Health Technology |
Vernalis Group Plc
 Vernalis Group Plc Pharmaceuticals: MajorHealth Technology Vernalis Group Plc a UK based company engages in research and development of pharmaceutical products.The current status of the company is extinct. | Health Technology |
| Naimark & Associates PC | |
| R.W. Johnson Pharmaceutical Research Institute | |
| Matrix Pharmaceuticals, Inc. |
- Bolsa de valores
- Insiders
- Marvin E. Jaffe